RESIST-TB Webinar Series – The V-QUIIN MDR Trial
RESIST-TB movement welcomes you to join an online presentation from Greg Fox, PhD MMBS FRACP MBBS MIPH on the V-QUIN MDR Trial. the presentation will take pleace on Thursday, November 3rd, from 08:00 to 9:00 EST (13:00-14:00 CET).
The V-QUIN Trial is a randomized controlled trial that aims to evaluate six months of daily levofloxacin versus six months of placebo as preventative therapy among household contacts of patients with MDR-TB. The V-QUIN Trial is enrolling children, adolescents, and infants regardless of HIV status. Currently, the V-QUIN Trial is enrolling participants in Vietnam.
To join the event as an attendee, 1) Go to https://hms.webex.com/hms/onstage/g.php?MTID=e52c5fa4a93e6022b01ab27f808333b04, 2) Click “Join Now”.
To join the audio conference only:
Call-in toll-free number (US/Canada): 1-877-668-4490
Call-in toll number (US/Canada): 1-408-792-6300
Global call-in numbers: https://hms.webex.com/hms/globalcallin.php?serviceType=EC&ED=507895452&tollFree=1
Toll-free dialing restrictions: https://www.webex.com/pdf/tollfree_restrictions.pdf
Access code: 715 273 202
To contact your host, RESIST-TB, send a message to or
The playback of UCF (Universal Communications Format) rich media files requires appropriate players. To view this type of rich media files in the meeting, please check whether you have the players installed on your computer by going to https://hms.webex.com/hms/onstage/systemdiagnosis.php
IMPORTANT NOTICE: This WebEx service includes a feature that allows audio and any documents and other materials exchanged or viewed during the session to be recorded. By joining this session, you automatically consent to such recordings. If you do not consent to the recording, discuss your concerns with the meeting host prior to the start of the recording or do not join the session. Please note that any such recordings may be subject to discovery in the event of litigation
RESIST-TB is a movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis, with a commitment to address the substantial existing gaps in our knowledge and to help provide access to an effective cure and prophylaxis of drug-resistant tuberculosis throughout the world.
To find out more about RESIST-TB’s work as well as the latest news and publications on MDR-TB, please visit our website at www.resisttb.org